Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, on the coming importance of being tested for the ARV7 marker and future treatments for patients with the marker.
Emmanuel S. Antonarakis, MBBCh, associate professor, Johns Hopkins Medicine, discusses the coming importance of being tested for the ARV7 marker and future treatments for patients with the marker. Antonarakis says in the future, the ARV7 marker could be an indicator for certain treatments like an androgen receptor therapy, such as enzalutamide or abiraterone, or a chemotherapy like docetaxel or cabazitaxel.
Antonarakis adds that it is only a matter of time before phase II and phase III trials will be available for oncologists to put patients on, specifically patients who express ARV7.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More